Slide 1: Third Quarter 2024 Financial Results and Corporate Update
Immunic Therapeutics Third Quarter 2024 Financial Results and Corporate Update NASDAQ: IMUX | November 7, 2024
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the saf e harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securitie
Slide 3: Agenda
Agenda Third Quarter 2024 Financial Results and Corporate Update 01 Third Quarter 2024 and Subsequent Highlights 04 Q&A Session 02 Financial and Operating Results 05 Summary and Highlights 03 Anticipated Clinical Milestones 3 | © Immunic, Inc. | Nov/07/2024
Slide 4: Third Quarter 2024 and Subsequent Highlights
01 Third Quarter 2024 and Subsequent Highlights
Slide 5: July: Strengthened Management Team
July: Strengthened Management Team Jason Tardio Appointed Werner Gladdines Promoted President and Chief Operating Officer Chief Development Officer ▪ Brings extensive ▪ Joined Immunic in multiple sclerosis drug January 2021; has commercialization held positions of experience to Immunic increasing re
Slide 6: July: Strengthened Board of Directors with Senior Pharmaceutical Executive
July: Strengthened Board of Directors with Senior Pharmaceutical Executive and Thought Leader in Brain Health Simona Skerjanec, M.Pharm, MBA ▪ Thought-leader in brain health with decades of experience in drug development and commercialization in the United States and internationally ▪ Has led resear
Slide 7: September: Hosted In-Person Multiple Sclerosis R&D Day in New York City
September: Hosted In-Person Multiple Sclerosis R&D Day in New York City Vidofludimus Calcium’s Profile and Positioning as a Potentially Groundbreaking Multiple Sclerosis Therapy Featured experts: ▪ Francesca Montarolo, Ph.D., Neuroscience Institute Cavalieri Ottolenghi (NICO) and University of Turin
Slide 8: September: Enrolled First Patient in Investigator-Sponsored Phase 2 Trial in Post COVID Syndrome
September: Enrolled First Patient in Investigator-Sponsored Phase 2 Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome* Potential Read-Through to Multiple Sclerosis Development Program ▪ In addition to post COVID readouts, designed to deliver data on Coordinating Investigator activit
Slide 9: September: Presented Key Vidofludimus Calcium Data at ECTRIMS Congress
September: Presented Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS Serum Neurofilament Changes in Progressive MS: Exploring the Potential of Vidofludimus Calcium to Reduce Fatigue Exploring the Impact of Vidofludimus Calcium by Age and in Multiple Sclerosis by Preventing Epstein-Barr
Slide 10: October: Positive Outcome of Interim Analysis of Phase 3 ENSURE Program
October: Announced Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing MS Assumptions Results ▪ Based on a pre-specified assessment after ▪ Two decisions made by the unblinded IDMC: approximately half of the planned first relapse – First question, whet
Slide 11: Financial and Operating Results
02 Financial and Operating Results
Slide 12: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months Nine Months Ended September 30, Ended September 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 21,370 $ 19,796 $ 58,429 $ 63,931 General and administrati
Slide 13: Anticipated Clinical Milestones
03 Anticipated Clinical Milestones
Slide 14: Several Clinical Value Inflection Points Ahead
Several Clinical Value Inflection Points Ahead IMU-838 ▪ Top-line data from phase 2 CALLIPER trial in PMS expected in April 2025 ▪ Completion of phase 3 ENSURE-1 trial IMU-838 anticipated in Q2/2026, ENSURE-2 expected in RMS in H2/2026 ▪ Phase 2 clinical trial in preparation IMU-856 ▪ Potentially ap
Slide 15: Vidofludimus Calcium Has the Potential to Transform the Oral Multiple Sclerosis DMT Market
Vidofludimus Calcium Has the Potential to Transform the Oral Multiple Sclerosis DMT Market Designed to Combine the Best of Two Worlds: Neuroprotection and Relapse Prevention First-in-class, dual mode of action approach designed to address the full spectrum of disease: ▪ Nurr1 activation provides dir
Slide 16: Q&A Session
04 Q&A Session
Slide 17: Summary and Highlights
05 Summary and Highlights
Slide 18: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Key Program Updates ✓ Phase 2 EMPhASIS trial in relapsing-remitting MS successfully completed Relapsing Multiple Sclerosis (RMS) – ENSURE-1 and ENSURE-2 Trial
Slide 19: Thank You!
Thank You! Immunic, Inc. Immunic AG 1200 Avenue of the Americas Lochhamer Schlag 21 New York City, NY 10036 82166 Gräfelfing (Munich) USA Germany Jessica Breu Vice President Investor Relations & Communications Immunic Australia Pty. Ltd. Melbourne Phone: +1-332-255-9819 Australia Email: ir@imux.com